BioMarin Pharmaceutical Financial Statements (BMRN)
|
|
|
|
Report date
|
|
|
31.12.2022 |
27.02.2023 |
26.02.2024 |
24.02.2025 |
26.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2 096 |
2 096 |
2 419 |
2 854 |
3 221 |
|
3 242 |
|
Operating Income, bln rub |
|
|
149.6 |
161.0 |
185.8 |
484.2 |
533.5 |
|
459.9 |
|
EBITDA, bln rub |
? |
|
165.7 |
265.4 |
306.8 |
650.5 |
572.9 |
|
464.0 |
|
Net profit, bln rub |
? |
|
141.6 |
141.6 |
167.6 |
426.9 |
348.9 |
|
268.7 |
|
|
OCF, bln rub |
? |
|
175.9 |
175.9 |
159.3 |
572.8 |
828.0 |
|
874.3 |
|
CAPEX, bln rub |
? |
|
121.0 |
121.0 |
96.7 |
97.4 |
103.0 |
|
107.2 |
|
FCF, bln rub |
? |
|
54.9 |
54.9 |
62.6 |
475.4 |
725.0 |
|
767.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
1 946 |
1 432 |
1 701 |
1 789 |
1 951 |
|
2 023 |
|
Cost of production, bln rub |
|
|
483.7 |
503.0 |
532.1 |
580.2 |
736.8 |
|
780.3 |
|
R&D, bln rub |
|
|
649.6 |
649.6 |
746.8 |
747.2 |
921.9 |
|
942.0 |
|
Interest expenses, bln rub |
|
|
16.0 |
16.0 |
17.3 |
12.7 |
10.9 |
|
23.0 |
|
|
Assets, bln rub |
|
|
6 375 |
6 375 |
6 842 |
6 989 |
7 594 |
|
8 591 |
|
Net Assets, bln rub |
? |
|
4 603 |
4 603 |
4 952 |
5 658 |
6 087 |
|
6 212 |
|
Debt, bln rub |
|
|
1 083 |
1 093 |
1 096 |
649.5 |
642.9 |
|
1 430 |
|
Cash, bln rub |
|
|
1 292 |
1 292 |
1 074 |
1 138 |
1 561 |
|
2 222 |
|
Net debt, bln rub |
|
|
-208.5 |
-198.1 |
21.9 |
-488.2 |
-917.7 |
|
-792.2 |
|
|
Ordinary share price, rub |
|
|
103.5 |
103.5 |
96.4 |
65.7 |
59.4 |
|
54.1 |
|
Number of ordinary shares, mln |
|
|
185.3 |
185.3 |
187.8 |
190.0 |
191.8 |
|
192.5 |
|
|
Market cap, bln rub |
|
|
19 173 |
19 173 |
18 111 |
12 490 |
11 398 |
|
10 406 |
|
EV, bln rub |
? |
|
18 965 |
18 975 |
18 133 |
12 002 |
10 480 |
|
9 614 |
|
Book value, bln rub |
|
|
4 068 |
4 068 |
4 461 |
5 207 |
5 677 |
|
5 811 |
|
|
EPS, rub |
? |
|
0.76 |
0.76 |
0.89 |
2.25 |
1.82 |
|
1.40 |
|
FCF/share, rub |
|
|
0.30 |
0.30 |
0.33 |
2.50 |
3.78 |
|
3.98 |
|
BV/share, rub |
|
|
22.0 |
22.0 |
23.7 |
27.4 |
29.6 |
|
30.2 |
|
|
EBITDA margin, % |
? |
|
7.90% |
12.7% |
12.7% |
22.8% |
17.8% |
|
14.3% |
|
Net margin, % |
? |
|
6.75% |
6.75% |
6.93% |
15.0% |
10.8% |
|
8.29% |
|
FCF yield, % |
? |
|
0.29% |
0.29% |
0.35% |
3.81% |
6.36% |
|
7.37% |
|
ROE, % |
? |
|
3.08% |
3.08% |
3.39% |
7.54% |
5.73% |
|
4.33% |
|
ROA, % |
? |
|
2.22% |
2.22% |
2.45% |
6.11% |
4.59% |
|
3.13% |
|
|
P/E |
? |
|
135.4 |
135.4 |
108.0 |
29.3 |
32.7 |
|
38.7 |
|
P/FCF |
|
|
349.0 |
349.0 |
289.5 |
26.3 |
15.7 |
|
13.6 |
|
P/S |
? |
|
9.15 |
9.15 |
7.49 |
4.38 |
3.54 |
|
3.21 |
|
P/BV |
? |
|
4.71 |
4.71 |
4.06 |
2.40 |
2.01 |
|
1.79 |
|
EV/EBITDA |
? |
|
114.5 |
71.5 |
59.1 |
18.4 |
18.3 |
|
20.7 |
|
Debt/EBITDA |
|
|
-1.26 |
-0.75 |
0.07 |
-0.75 |
-1.60 |
|
-1.71 |
|
|
R&D/CAPEX, % |
|
|
537.0% |
537.0% |
772.3% |
767.0% |
894.7% |
|
878.8% |
|
|
CAPEX/Revenue, % |
|
|
5.77% |
5.77% |
4.00% |
3.41% |
3.20% |
|
3.31% |
|
| BioMarin Pharmaceutical shareholders |
